Tempus AI's XR Assay Receives EU Certification As A Class C In Vitro Diagnostic Device
The certification covers Tempus’ quality management system for "next-generation sequencing devices for cancer genomic profiling to support clinical management."xR detects gene rearrangements and specific splice
Tempus AI got official permission to sell a cancer testing tool in Europe. This means the company can now reach more patients and doctors overseas.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.